The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group
Abstract
Purpose: To determine the response rate and toxicity of flavopiridol in patients with previously untreated or relapsed mantle-cell lymphoma. Patients and Methods: Adult patients with previously untreated or in first or second relapse of previously responsive mantle-cell lymphoma were given flavopiridol 50 mg/m 2/d by intravenous bolus for 3 consecutive days every 21 days with antidiarrheal prophylaxis. Flavopiridol was continued until disease progression, unacceptable toxicity, or stable disease for four cycles. Disease was reassessed every two cycles. Results: From 33 registered patients, 30 were eligible after pathology review, 30 were assessable for toxicity, and 28 were assessable for response. A median of four cycles of treatment was administered; 90% of patients received at least 90% of planned dose-intensity. No complete responses were seen; three patients had a partial response (11%), 20 patients had stable disease (71%), and five patients had progressive disease (18%). The median duration of response was 3.3 months (range, 2.8 to 13.2 months). The most common toxicities were diarrhea (97%), fatigue (73%), nausea (47%), and vomiting (27%). At least one nonhematologic grade 3 or 4 toxicity was seen in 14 patients (47%). Hematologic toxicity was modest. Conclusions: Flavopiridol given as a daily bolus for 3 consecutive days every 3 weeks has modest activity as a single agent for mantle-cell lymphoma. The number of stable and partial responses that was seen indicates that it is biologically active and may delay progression. Future studies in mantle-cell lymphoma should test this agent with other active agents and using different schedules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationHarris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
The Non-Hodgkin's Lymphoma Pathologic Classification Project (1982) · Cancer · doi:10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2 · Cited by 3,059
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,461
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
One-Sample Multiple Testing Procedure for Phase II Clinical Trials
Fleming, T. R. (1982) · Biometrics · doi:10.2307/2530297 · Cited by 1,003
Patient preferences for oral versus intravenous palliative chemotherapy.
Liu, G., Franssen, E., Fitch, M. I., & Warner, E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.110 · Cited by 919
Tsujimoto, Y., Yunis, J., Onorato-Showe, L., Erikson, J., Nowell, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6610211 · Cited by 652
Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
Mantle Cell Lymphoma A Proposal for Unification of Morphologic, Immunologic, and Molecular Data
Banks, P. M., Chan, J., Cleary, M. L., Delsol, G., De Wolf-Peeters, C., Gatter, K., Grogan, T. M., Harris, N. L., Isaacson, P. G., Jaffe, E. S., et al. (1992) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199207000-00001 · Cited by 508
Tsujimoto, Y., Jaffe, E., Cossman, J., Gorham, J., Nowell, P. C., & Croce, C. M. (1985) · Nature · doi:10.1038/315340a0 · Cited by 422
Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2986 · Cited by 403
Ishikawa, T., Utoh, M., Sawada, N., Nishida, M., Fukase, Y., Sekiguchi, F., & Ishitsuka, H. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00682-5 · Cited by 325
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
Fumoleau, P., Delgado, F. M., Delozier, T., Monnier, A., Gil Delgado, M. A., Kerbrat, P., Garcia-Giralt, E., Keiling, R., Namer, M., & Closon, M. T. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1245 · Cited by 320
Kitada, S., Zapata, J. M., Andreeff, M., & Reed, J. C. (2000) · Blood · doi:10.1182/blood.v96.2.393 · Cited by 264
Bible, K. C., & Kaufmann, S. H. (1997) · PubMed · Cited by 258
Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Koss, W., Morgan, C. D., Stinson, S. F., et al. (1998) · PubMed · doi:10.1182/blood.v91.7.2482 · Cited by 240
König, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., & Gabrilove, J. L. (1997) · Blood · doi:10.1182/blood.v90.11.4307 · Cited by 191
Bible, K. C., & Kaufmann, S. H. (1996) · PubMed · Cited by 189
Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma
de Boer, C., Schuuring, E., Dreef, E., Peters, G., Bartek, J., Kluin, P., & van Krieken, J. (1995) · Blood · doi:10.1182/blood.v86.7.2715.2715 · Cited by 188
Vinorelbine as first-line chemotherapy for metastatic breast carcinoma.
Romero, A., Rabinovich, M. G., Vallejo, C. T., Perez, J. E., Rodriguez, R., Cuevas, M. A., Machiavelli, M., Lacava, J. A., Langhi, M., & Romero Acuña, L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.336 · Cited by 185
Motwani, M., Delohery, T. M., & Schwartz, G. K. (1999) · PubMed · Cited by 173
Schwartz, G. K., O'Reilly, E. M., Ilson, D. H., Saltz, L. B., Sharma, S., Tong, W. P., Maslak, P. G., Stoltz, M., Eden, L., Perkins, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.080 · Cited by 155
Melillo, G., Sausville, E. A., Cloud, K., Lahusen, T. J., Varesio, L., & Senderowicz, A. M. (1999) · PubMed · Cited by 142
Judson, I. R., Beale, P. J., Trigo, J. M., et al. (1999) · Investigational New Drugs · doi:10.1023/a:1006263400888 · Cited by 121
Motwani, M., Jung, C. P., Sirotnak, F. M., She, Y., Shah, M. A., Gönen, M., & Schwartz, G. K. (2001) · PubMed · Cited by 116
Jung, C. P., Motwani, M., & Schwartz, G. K. (2001) · PubMed · Cited by 106
Jassem, J., Ramlau, R., Karnicka-Młodkowska, H., Krawczyk, K., Krzakowski, M. J., Zatloukal, P., Lemarié, É., Hartmann, W., Novakova, L., O’Brien, M., et al. (2001) · Annals of Oncology · doi:10.1023/a:1012539225493 · Cited by 101
Senderowicz, A. M. (2001) · Leukemia · doi:10.1038/sj.leu.2401994 · Cited by 96
Seventy-Two Hour Continuous Infusion Flavopiridol in Relapsed and Refractory Mantle Cell Lymphoma
Lin, T. S., Howard, O. M., Neuberg, D. S., et al. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190290016908 · Cited by 75
Nguyen, L., Tranchand, B., Puozzo, C., & Variol, P. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01581.x · Cited by 56
Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer
Acuña, L. R., Langhi, M., Pérez, J., Acuña, J. R., Machiavelli, M., Lacava, J., Vallejo, C., Romero, A., Fasce, H., Ortiz, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.74 · Cited by 54
Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol
Semenov, I., Akyüz, C., Roginskaya, V. Y., Chauhan, D., & Corey, S. J. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00103-5 · Cited by 51
Sadahiro, S., Suzuki, T., KAMEYA, T., et al. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000243 · Cited by 21
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Self-citationLenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Metadata
- Authors
- Kouroukis, C. T., Belch, A., Crump, M., Eisenhauer, E., Gascoyne, R. D., Meyer, R., Lohmann, R., Lopez, P., Powers, J., Turner, R., & Connors, J. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-05-01
- Volume
- 21
- Issue
- 9
- Pages
- 1740-1745
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139582914
- Cited by
- 277
- References
- 37
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.